ATP1A1 is a promising new target for melanoma treatment and can be inhibited by its physiological ligand bufalin to restore targeted therapy efficacy.

Auteurs

Soumoy L, Genbauffe A, Mouchart L, Sperone A, Trelcat A, Mukeba-Harchies L, Wells M, Blankert B, Najem A, Ghanem G, Saussez S, Journe F

  • Date de publication

    Janvier 2024

  • Type

    Article

  • Revue

    Cancer Cell Int

  • Nom du chercheur

    GHANEM GHANEM

  • Hôpital

    Institut Jules Bordet

  • Service

    Radiopharmacie

  • PMID

    38178183

  • DOI

    10.1186/s12935-023-03196-y